| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $33,322,848 ) (Continued on the next page) |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01DE029510 | Craniofacial microsomia: Accelerating Research and Education (CARE) | 000 | 4 | NIH | 2/22/2023 | $571,375 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI155536 | Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | 000 | 3 | NIH | 11/1/2022 | $829,484 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | F32HL154558 | Rhythmogenic states of the respiratory network reveal differential opioid sensitivity | 000 | 3 | NIH | 12/30/2022 | $69,802 |
| | 2023 | 2023 | Seattle Children's Hospital | 4800 Sand Point Way NE | Seattle | WA | 98105-3916 | KING | USA | T2331575 | Children's Hospitals Graduate Medical Education Payment Program | 00 | 6 | HRSA | 12/14/2022 | $795,812 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 Sand Point Way NE | Seattle | WA | 98105-3916 | KING | USA | T2331575 | Children's Hospitals Graduate Medical Education Payment Program | 01 | 6 | HRSA | 3/2/2023 | $1,579,494 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 Sand Point Way NE | Seattle | WA | 98105-3916 | KING | USA | T2331575 | Children's Hospitals Graduate Medical Education Payment Program | 01 | 6 | HRSA | 3/2/2023 | $2,683,058 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI177257 | Perturbations of host cell signaling by a complex hepatotropic pathogen | 000 | 11 | NIH | 2/23/2023 | $629,962 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R37CA266777 | The IL-18-IFN? axis predicts response to immunotherapy | 000 | 1 | NIH | 1/27/2023 | $845,823 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01EY033364 | Optimizing Models of Non-Coding Genetic Risk in Age-Related Macular Degeneration | 000 | 2 | NIH | 2/27/2023 | $492,250 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI163160 | Dysregulated asthmatic epithelial interferon responses to viruses drive exacerbation, T2 inflammation, and airway remodeling | 000 | 2 | NIH | 2/1/2023 | $863,906 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AG062738 | Pericyte structural plasticity and cerebrovascular health | 000 | 4 | NIH | 2/15/2023 | $562,068 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | K08AI166072 | Dissecting the molecular regulation of T cell localization and function within the Mycobacterium tuberculosis granuloma | 000 | 2 | NIH | 1/5/2023 | $186,489 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | F31AI167494 | Characterization of P. falciparum gametocyte-essential genes using a novel genetic screen | 000 | 2 | NIH | 1/25/2023 | $46,752 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AG062738 | Pericyte structural plasticity and cerebrovascular health | 001 | 4 | NIH | 2/23/2023 | $112,893 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | F31AI167494 | Characterization of P. falciparum gametocyte-essential genes using a novel genetic screen | 001 | 2 | NIH | 3/2/2023 | $942 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI158536 | Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | 000 | 2 | NIH | 2/1/2023 | $843,868 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | K24AI150991 | Clinical Impacts of Heterogeneous Interferon Responses to Viral Infection by Asthmatic Airway Epithelium | 000 | 4 | NIH | 1/31/2023 | $184,530 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI172824 | Parasite and host cell factors involved in the formation and persistence of?Plasmodium vivax?hypnozoites | 000 | 1 | NIH | 2/9/2023 | $658,690 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | F32HL159904 | Dynamic switching in the brainstem: a spatiotemporal mechanism for the neural control of breathing | 000 | 2 | NIH | 1/31/2023 | $67,582 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R50CA275857 | Pediatric brain tumors: Improving survival through integration of clinical molecular diagnostics and biologically targeted therapies into clinical trials | 000 | 1 | NIH | 3/21/2023 | $175,338 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01HL166317 | Unraveling a parabrachial circuit for the state-dependent control of rapid breathing | 000 | 1 | NIH | 12/30/2022 | $746,089 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | F32HL160102 | Characterizing the neural circuitry of postinspiratory behaviors and its coordination with breathing | 000 | 2 | NIH | 2/15/2023 | $71,792 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01ES033785 | Assessing how Prenatal Phthalate Exposure Disrupts Placental Transcriptional Regulation and Contributes to Changes in Gestational Length | 000 | 1 | NIH | 1/10/2023 | $660,101 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | K23HD103872 | Improving Diversity in Neonatal Clinical Trial Enrollment | 000 | 3 | NIH | 2/23/2023 | $160,791 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AR075813 | Impact of Loss-of-function NADPH Oxidase Variants on B cell Activation in SLE | 000 | 3 | NIH | 2/28/2023 | $536,554 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01DE032663 | Influence of viral and immune interventions on early events following oral SIV infection | 000 | 1 | NIH | 1/12/2023 | $837,728 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AR076978 | Three-model platform for understanding DMD epigenetic mechanisms and advancing small molecule therapies | 000 | 3 | NIH | 1/31/2023 | $495,001 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01CA114567 | Targeted Therapy in Ex Vivo Medulloblastoma | 000 | 15 | NIH | 2/10/2023 | $438,734 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01CA114567 | Targeted Therapy in Ex Vivo Medulloblastoma | 001 | 15 | NIH | 2/15/2023 | $137,426 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI170914 | Functional exploration of a deep Mycobacterium tuberculosis phosphoproteome | 000 | 1 | NIH | 2/3/2023 | $617,255 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01HL163103 | Hexosamine biosynthesis pathway metabolism during cardiac hypertrophy | 000 | 1 | NIH | 12/20/2022 | $750,797 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | U01AI155335 | Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | 002 | 3 | NIH | 1/6/2023 | $1,242,198 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R03DK134746 | The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes | 000 | 1 | NIH | 1/30/2023 | $147,675 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI140951 | Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers | 000 | 5 | NIH | 1/4/2023 | $856,679 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI137234 | Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse | 000 | 5 | NIH | 12/1/2022 | $822,542 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | U01AI142001 | Inducing durable, protective immune memory against malaria | 000 | 5 | NIH | 12/12/2022 | $802,689 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01HD106628 | Supraphysiologic Shear Stresses Associated with Cardiopulmonary Bypass are Sufficient to Activate RIKP3 Signaling | 000 | 2 | NIH | 2/23/2023 | $801,557 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R35GM139566 | Volatile Anesthetics and Metabolism | 000 | 3 | NIH | 3/2/2023 | $819,975 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | P01HD104435 | Utilization of Advanced Technologies for the Understanding of Human Structural Birth Defects | 001 | 3 | NIH | 2/10/2023 | $160,395 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | K01HG010361 | Respect for Persons in the Genomics Research Enrollment Process: Incorporating Diverse Experiences and Attitudes | 001 | 5 | NIH | 12/21/2022 | $124,817 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | U54AI170855 | Behavior of HIV in Viral Environments (B-HIVE) | 000 | 2 | NIH | 3/20/2023 | $5,956,849 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | P01HD104435 | Utilization of Advanced Technologies for the Understanding of Human Structural Birth Defects | 000 | 3 | NIH | 12/21/2022 | $1,443,563 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R21DC018341 | Transcriptome-driven inference of adverse drug interactions | 000 | 3 | NIH | 12/20/2022 | $167,400 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | U01AI165455 | Collective Responses to Malaria Vaccination | 000 | 2 | NIH | 12/20/2022 | $700,000 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R21DC018341 | Transcriptome-driven inference of adverse drug interactions | 001 | 3 | NIH | 1/18/2023 | $18,600 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | K99CA267481 | Addressing Social Needs of Adolescents and Young Adults (AYAs) with Cancer | 000 | 2 | NIH | 1/31/2023 | $114,981 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01AI152268 | FXIIIA production by mast cells for innate immunity | 000 | 4 | NIH | 3/21/2023 | $755,460 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R01MH113545 | Investigating the synaptic pathology of Autism | 000 | 6 | NIH | 1/19/2023 | $792,960 |
| | 2023 | 2023 | SEATTLE CHILDREN'S HOSPITAL | 4800 SAND POINT WAY NE | SEATTLE | WA | 98105-3916 | KING | USA | R21HS029399 | Inform Shared Decision-making with Advanced Bayesian Causal Inference to Improve Quality of Pediatric Rheumatology Care | 000 | 1 | AHRQ | 3/13/2023 | $151,950 |
|
